CRISPR Therapeutics AG

CRISPR Therapeutics AG is a Swiss-American biotechnology company headquartered in Zug, Switzerland, with its U.S. headquarters and R&D operations in Boston, Massachusetts. The company's core mission is to develop transformative gene-based medicines for serious diseases by leveraging its proprietary CRISPR/Cas9 gene editing platform.

CRISPR Therapeutics has a diverse portfolio of therapeutic programs spanning hemoglobinopathies, oncology, diabetes, and cardiovascular diseases. Its lead product, exagamglogene autotemcel (exa-cel), marketed as CASGEVY™, was developed in collaboration with Vertex Pharmaceuticals and received regulatory approval in December 2023 for the treatment of sickle cell disease and transfusion-dependent beta thalassemia, marking it as the first-ever approved CRISPR-based therapy. The company's pipeline also includes CAR T cell therapies (e.g., CTX112, CTX131) for oncology and autoimmune indications, and in vivo gene editing programs (e.g., CTX310, CTX320, CTX340, CTX611) for cardiovascular diseases and Type 1 Diabetes.

Under the leadership of CEO Samarth Kulkarni, CRISPR Therapeutics is navigating the commercialization phase of CASGEVY™, with anticipated global regulatory submissions for younger patients and updates from various clinical programs expected in 2026. Despite the scientific breakthrough of CASGEVY™, the company reported $1.46 million in revenue against a net loss of $122.9 million in Q1 2026, highlighting the challenges in translating scientific success into commercial profitability. The company maintains a strong financial position, holding approximately $2.4 billion in cash and equivalents as of Q1 2026, providing substantial flexibility for ongoing research and development.